Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

NCT02438722 2026-05-18

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2/3 Completed

174 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04702009 2026-04-29

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

Phase 2/3 Completed

33 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

492 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT04206072 2025-08-11

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Phase 2/3 Completed

362 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05807893 2024-11-13

SUPER BRAIN

Phase 2/3 Completed

40 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT00245154 2023-08-04

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 2/3 Completed

296 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01905657 2021-10-06

MK-3475-010

Phase 2/3 Completed

1,034 enrolled 16 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT00006229 2020-04-06

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2/3 Completed

774 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01631357 2019-11-05

CIK

Phase 2/3 Completed

96 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

NCT00775307 2019-09-24

Adjuvant Pazopanib in Stage I NSCLC

Phase 2/3 Completed

142 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02284139 2018-04-23

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

Phase 2/3 Completed

90 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02388919 2017-09-18

ALTER0303

Phase 2/3 Completed

439 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00775385 2017-03-03

TASTE

Phase 2/3 Completed

152 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00415818 2014-07-16

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2/3 Completed

148 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00253591 2013-12-19

Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Phase 2/3 Completed

500 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01528488 2013-11-05

Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC

Phase 2/3 Completed

118 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00021060 2013-02-27

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

Phase 2/3 Completed

842 enrolled

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00002930 2013-01-18

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

Phase 2/3 Completed

75 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT01494558 2011-12-19

Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer

Phase 2/3 Completed

200 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00752115 2011-09-07

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Completed

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00312819 2010-08-31

Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer

Phase 2/3 Completed

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

SKYSCRAPER-06

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer

BM

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

SUPER BRAIN

Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

MK-3475-010

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

CIK

Adjuvant Pazopanib in Stage I NSCLC

Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects

ALTER0303

TASTE

Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer

PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery

Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy to Treat Non-Small Cell Lung Cancer

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Initial Assessment of the Effect of the Addition of Disulfiram (Antabuse) to Standard Chemotherapy in Lung Cancer